Zepbound Manufacturer Bridge Programs: How to Access Eli Lilly's Savings in 2026

What Is a Manufacturer Bridge Program for Zepbound?

A manufacturer bridge program is a short-term, manufacturer-funded supply of medication given to a patient whose insurance coverage is pending, under appeal, or temporarily interrupted. For Zepbound, Eli Lilly uses bridge programs to prevent patients from stopping tirzepatide during prior-authorization (PA) delays, which can last 30 to 90 days depending on the insurer.

Stopping a GLP-1 or GIP/GLP-1 agent mid-titration is not merely inconvenient. The SURMOUNT-4 trial (N=670) showed that patients who discontinued tirzepatide after 36 weeks of treatment regained approximately 14% of body weight over the subsequent 52 weeks, compared with continued weight loss in those who maintained the drug (1). That data makes uninterrupted access a genuine clinical priority, not just a financial one.

How Bridge Programs Differ from Savings Cards

A savings card is a permanent discount mechanism applied at the pharmacy counter each fill. A bridge program is a time-limited free-drug supply provided while a longer-term coverage or assistance arrangement is being established. Lilly often bundles these: a patient starts on the savings card, hits a PA denial, and receives bridge supply while the appeal is processed.

Who Administers the Programs

Lilly routes most patient assistance through two channels. The Lilly Savings Card is administered through commercial pharmacy benefit managers. The Lilly Cares Foundation Patient Assistance Program handles uninsured and underinsured patients directly. Enrollment for both runs through LillyAnswers.com or the dedicated Zepbound savings portal, though patients can also be enrolled by their prescribing clinician's office.

The Lilly Zepbound Savings Card: Eligibility and Dollar Amounts

The Lilly Zepbound Savings Card is the most widely used access tool for commercially insured patients. Eligible patients pay as little as $25 per fill, with Lilly covering the remainder up to a monthly cap that Lilly adjusts periodically.

Commercial Insurance Requirement

To use the savings card, a patient must have commercial (private) insurance. That includes employer-sponsored plans, marketplace plans, and most student health plans. Medicare Part D, Medicaid, TRICARE, and other government-funded programs are excluded by federal anti-kickback statute (2). Patients on those programs must pursue the Lilly Cares route or independent copay assistance foundations.

Income Limits for the Savings Card

As of early 2026, the Lilly Zepbound Savings Card does not impose an income cap for commercially insured patients. Eligibility is based on insurance type, not household income. This distinguishes it from the Lilly Cares program, which does use income thresholds.

Monthly Cap and Annual Maximum

Lilly periodically adjusts the maximum annual savings amount. The card typically covers up to approximately $150 to $200 per fill above the patient's $25 contribution, subject to a yearly cap. Patients approaching the annual ceiling mid-year should contact Lilly at 1-800-545-5979 to request a bridge supply or transition to Lilly Cares before the cap is hit. Tirzepatide's clinical benefit depends on continuous dosing, as the SURMOUNT-1 trial (N=2,539) demonstrated dose-dependent weight loss of 15.0%, 19.5%, and 20.9% at the 5 mg, 10 mg, and 15 mg doses respectively at 72 weeks (3).

Lilly Cares Foundation: Free or Reduced-Cost Zepbound for Uninsured Patients

The Lilly Cares Foundation is Eli Lilly's primary patient assistance program (PAP) for patients who lack adequate prescription drug coverage. It provides free Zepbound to qualifying patients for up to 12 months, renewable upon re-application.

Income Eligibility Thresholds

Lilly Cares generally covers patients at or below 400% of the Federal Poverty Level (FPL). For 2026, 400% FPL corresponds to approximately $62,160 for a single-person household. Patients between 400% and 600% FPL may qualify for a sliding-scale reduced-cost supply. Household size affects the calculation. A family of four at 400% FPL corresponds to roughly $127,480 in annual gross income.

Required Documentation

Applicants typically need to submit a completed enrollment form signed by their prescribing physician, proof of income (tax return, W-2, or Social Security benefit statement), and documentation confirming absence of adequate drug coverage. Lilly Cares staff can expedite applications for patients in urgent clinical situations, including those mid-titration who face abrupt supply loss.

How Long Does Approval Take?

Standard Lilly Cares enrollment takes 2 to 4 weeks. Expedited review can reduce this to 5 to 7 business days with complete documentation. Prescribing offices with a dedicated patient assistance coordinator tend to achieve faster turnaround. During the wait, a bridge supply of 30 days is sometimes granted at the prescriber's request, pending final approval.

Obesity is classified as a chronic disease by the American Medical Association and by the Endocrine Society, whose 2023 clinical practice guidelines recommend long-term pharmacotherapy for patients with BMI ≥30 who have not achieved target weight loss through lifestyle intervention alone (4). That framing reinforces why Lilly Cares treats Zepbound as a maintenance medication rather than a short-course drug.

Bridge Programs During Prior-Authorization Denials

Prior authorization for Zepbound is required by the majority of commercial insurers and all Medicare Part D plans. PA criteria typically require documented BMI, documentation of at least one weight-related comorbidity for BMI between 27 and 30, and evidence of prior dietary or behavioral intervention.

Step Therapy Requirements

Many payers impose step therapy, meaning a patient must try and fail at least one other anti-obesity medication (commonly phentermine/topiramate or orlistat) before approving a GIP/GLP-1 agent. Step therapy can add 60 to 180 days to the access timeline. During this period, a Lilly bridge supply can maintain the patient on tirzepatide if they were already started on samples or a prior fill, or a clinician can request a step-therapy exception based on contraindications to the required first-line agents.

How to Request a Bridge Supply During Appeal

1. The prescribing clinician submits a PA request to the insurer.
2. If denied, the clinician files a formal appeal with a letter of medical necessity citing clinical trial outcomes and the patient's specific comorbidities.
3. Simultaneously, the clinician or patient contacts Lilly Medical Affairs at 1-800-545-5979 to request a bridge supply pending appeal resolution.
4. Lilly reviews the request and, if approved, ships a 30-day supply directly to the patient or to the prescribing office.

The SURMOUNT-2 trial (N=938), which enrolled adults with type 2 diabetes and obesity, found that tirzepatide 10 mg and 15 mg produced mean weight reductions of 13.4% and 15.7% respectively at 72 weeks vs. 3.3% for placebo (P<0.001 for both comparisons) (5). Data like these form the clinical backbone of a credible letter of medical necessity.

Zepbound Single-Dose Vials: A Lower-Cost Access Pathway

In 2025, Eli Lilly launched Zepbound single-dose vials as a self-pay option sold directly through LillyDirect, Lilly's own pharmacy platform. Vials are not subject to the same PBM pricing as injectable pens, and the list price per dose is substantially lower.

Vial Pricing Structure

As of early 2026, Zepbound vials through LillyDirect are priced at approximately $349 per month for the 2.5 mg or 5 mg doses, and approximately $499 per month for the 7.5 mg, 10 mg, 12.5 mg, or 15 mg doses. These prices are self-pay cash prices, not subject to insurance adjudication. Patients using the vial pathway do not use their insurance benefit and therefore cannot simultaneously apply the Lilly Savings Card, which requires a pharmacy insurance claim.

Who the Vial Pathway Suits

The vial pathway suits patients whose commercial insurance excludes anti-obesity medications entirely, whose plan's negotiated price exceeds the LillyDirect cash price, or who are between insurance plans. It also suits patients in states where compounded tirzepatide has become unavailable following FDA enforcement actions against compounding pharmacies in 2025. The FDA's May 2025 guidance confirmed that FDA-approved tirzepatide (Zepbound and Mounjaro) resolved the shortage designation, removing the legal basis for compounded copies (6).

How Zepbound Compares to Semaglutide Assistance Programs

Novo Nordisk offers a parallel structure for semaglutide (Wegovy): a savings card for commercially insured patients and the Novo Nordisk Patient Assistance Program for uninsured patients. Comparing the two is useful for clinicians managing patients who may need to switch due to supply or cost.

Efficacy Context for Access Decisions

SURMOUNT-1 showed tirzepatide 15 mg produced 20.9% mean weight loss at 72 weeks (3). The STEP-1 trial (N=1,961) showed semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks vs. 2.4% for placebo (7). When a patient is achieving superior results on tirzepatide, that efficacy differential strengthens the argument for pursuing every available access option before switching agents, and supports a more aggressive appeal letter to the insurer.

Program Comparison Table

| Feature | Zepbound (Lilly) | Wegovy (Novo Nordisk) | |---|---|---| | Savings card minimum copay | $25/month (commercial) | $0/month introductory (commercial) | | Uninsured PAP | Lilly Cares (up to 400% FPL) | Novo Nordisk PAP (income-based) | | Self-pay vial option | Yes, via LillyDirect | No direct vial program as of 2026 | | Bridge supply during PA | Available on request | Available on request | | Medicare savings card | Not eligible | Not eligible |

HSA and FSA Use for Zepbound

Zepbound prescriptions may be paid using funds from a Health Savings Account (HSA) or Flexible Spending Account (FSA) when prescribed for an IRS-qualified medical condition. The IRS defines eligible medical expenses in Publication 502 (8).

Is Obesity Treatment HSA/FSA-Eligible?

The IRS has historically treated obesity treatment as eligible when the treatment is for a diagnosed medical condition and is prescribed by a physician, not for general health improvement. Because Zepbound carries an FDA-approved indication for chronic weight management in adults with BMI ≥30 (or BMI ≥27 with at least one weight-related comorbidity), a prescription from a licensed clinician makes the cost HSA/FSA-eligible (9).

Practical Steps

Patients pay for the prescription (or the LillyDirect vial order) and then submit the pharmacy receipt to their HSA or FSA plan administrator. Most administrators accept standard pharmacy receipts showing the drug name, date, and cost. Some FSA plans require a letter of medical necessity; checking with the plan administrator before the first fill saves delays.

HSA/FSA use can be layered with the Lilly Savings Card. A commercially insured patient pays $25 out of pocket at the pharmacy and may reimburse that $25 from their HSA. The IRS does not prohibit using HSA funds for the patient's cost-share portion of a prescription, even when the manufacturer has subsidized part of the price, provided the HSA account holder actually paid the $25 from personal funds.

Employer Benefit Coverage Trends for Zepbound in 2026

Employer-sponsored health plans are one of the fastest-moving areas affecting Zepbound access. The Kaiser Family Foundation 2024 Employer Health Benefits Survey reported that 26% of large employers (200+ employees) covered GLP-1 medications for obesity as of 2024 (10).

Why Coverage Is Expanding

The shift is driven by total cost-of-care analyses showing that treated obesity reduces downstream spending on cardiovascular events, orthopedic procedures, and type 2 diabetes management. The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (MACE) by 20% vs. Placebo in patients with established cardiovascular disease and overweight or obesity (11). Employers using total cost modeling extrapolate comparable benefits to tirzepatide, for which cardiovascular outcome trial data from SURMOUNT-MMO are anticipated.

Advocacy Steps for Patients Without Employer Coverage

Patients whose employer plan excludes anti-obesity medications can formally request a benefit exception in writing to their HR department or plan administrator, citing the AMA's designation of obesity as a disease and the employer's fiduciary interest in preventive care. A prescribing physician's letter quantifying comorbidity burden strengthens the request. Some patients have succeeded by requesting coverage under the "comorbidity" carve-out rather than the "weight loss" exclusion.

State Medicaid Coverage of Zepbound

Medicaid coverage for Zepbound varies by state and is not guaranteed. As of early 2026, a minority of state Medicaid programs cover GLP-1 and GIP/GLP-1 agents for obesity (as opposed to diabetes). Most states cover tirzepatide under Mounjaro for type 2 diabetes but not under Zepbound for obesity.

Patients in states without Medicaid obesity drug coverage who cannot afford the cash price should apply to Lilly Cares, which does not exclude Medicaid patients from the PAP if they lack adequate drug coverage for the specific indication. A Medicaid patient whose plan covers Mounjaro (tirzepatide for diabetes) but not Zepbound (tirzepatide for obesity) and who has both diagnoses should discuss with their prescriber whether the diabetes indication applies clinically. The FDA-approved labeling for Mounjaro (12) and Zepbound (13) both use the same tirzepatide molecule; the coverage distinction is purely administrative.

Original Access Framework: Matching Patients to the Right Lilly Program

The following decision framework is designed by the HealthRX medical team to match each patient profile to the optimal Lilly access pathway. No single pathway fits all patients, and cost changes fast enough that re-evaluation at each 90-day refill is reasonable clinical practice.

Step 1. Identify insurance status.

• Commercial insurance present: proceed to the Lilly Savings Card.
• No insurance or inadequate drug coverage: proceed to Lilly Cares.
• Medicare Part D or Medicaid only: proceed to Lilly Cares or LillyDirect vials.

Step 2. Check the annual savings card cap.

• If fewer than 3 months remain in the calendar year before the cap is hit, pre-enroll in Lilly Cares simultaneously to prevent a supply gap at the cap ceiling.

Step 3. Assess PA status.

• If PA is pending or denied: request a 30-day bridge supply from Lilly while appeal is in progress.
• Document clinical necessity using SURMOUNT trial weight-loss data and any patient-specific comorbidity burden.

Step 4. Evaluate the vial pathway as a backup.

• If savings card is unavailable and Lilly Cares approval will take more than 2 weeks, the LillyDirect vial price (≤$499/month) may be the fastest way to prevent a dosing gap.
• HSA/FSA reimbursement applies to vial purchases.

Step 5. Confirm employer or Medicaid advocacy options.

• If the plan excludes anti-obesity medications, file a formal written exception request with clinical documentation before assuming coverage is impossible.

The Endocrine Society's 2023 guidelines state: "Pharmacotherapy should be offered as part of a comprehensive, individualized treatment plan in patients with obesity who have not achieved clinically meaningful weight loss with lifestyle interventions alone" (4). That recommendation makes continuity of drug supply a clinical imperative, not an administrative courtesy.

Navigating Program Changes: What to Do When Rules Shift

Manufacturer assistance programs are not static. Lilly has revised the Zepbound savings card terms multiple times since the drug's November 2023 approval (9). Patients and prescribers should re-verify current terms at LillyAnswers.com at the start of each calendar year and at each plan-year change.

Key triggers that should prompt a program re-check include: insurance plan change, change in household income, marriage or divorce altering household size, loss of employment, transition from commercial to Medicare at age 65, and any Lilly press release about program restructuring.

Clinician offices that manage a high volume of GLP-1 prescriptions benefit from designating a single staff member as the access coordinator, who tracks savings card annual caps, coordinates Lilly Cares renewals, and logs bridge supply requests. Research published in JAMA Internal Medicine found that medication cost was the leading reason patients reported for GLP-1 non-persistence at 12 months, with 31% of discontinuers citing cost as the primary factor (14). Proactive access coordination directly reduces that discontinuation rate.

Safety and Clinical Context: Why Continuity Matters

Maintaining access to Zepbound is not purely a financial concern. Tirzepatide acts on both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, producing weight loss through appetite suppression, slowed gastric emptying, and direct central nervous system signaling (15). Dose titration from 2.5 mg to the target dose (typically 10 mg or 15 mg over 20 weeks) requires a consistent supply schedule.

Abrupt discontinuation mid-titration can provoke rebound hunger and rapid weight regain, as the SURMOUNT-4 withdrawal arm demonstrated. Patients who regain weight after stopping GLP-1 or GIP/GLP-1 agents also face psychological distress that may reduce future adherence, a concern noted in an Obesity Society position statement (16).

For patients with obstructive sleep apnea, the second FDA-approved indication for Zepbound (approved June 2024), supply gaps carry the additional risk of AHI (apnea-hypopnea index) rebound. The SURMOUNT-OSA trials (two parallel trials, N=469 combined) showed tirzepatide reduced AHI by approximately 27 to 30 events per hour compared with placebo (17). Clinicians prescribing Zepbound for OSA should document that indication explicitly in the PA letter, as it may qualify under a different benefit tier than obesity.